• Title of article

    Effect of idebenone on cardiomyopathy in Friedreichʹs ataxia: a preliminary study Original Research Article

  • Author/Authors

    Pierre Rustin، نويسنده , , Jürgen-Christoph von Kleist-Retzow، نويسنده , , Karine Chantrel-Groussard، نويسنده , , Daniel Sidi، نويسنده , , Arnold Munnich، نويسنده , , Agnès R?tig، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1999
  • Pages
    3
  • From page
    477
  • To page
    479
  • Abstract
    Background Friedreichʹs ataxia is caused by a deficiency of frataxin, a protein involved in regulation of mitochondrial iron content. We have reported a combined deficiency of a Krebscycle enzyme, aconitase, and three mitochondrial respiratorychain complexes in endomyocardial biopsy samples from patients with this disorder. All four enzymes share iron-sulphur cluster-containing proteins that are damaged by iron overload through generation of oxygen free radicals. We used an in-vitro system to elucidate the mechanism of iron-induced injury and to test the protective effects of various substances. On the basis of these results, we assessed the effect of idebenone (a free-radical scavenger) in three patients with Friedreichʹs ataxia. Methods Heart homogenates from patients with valvular stenosis were tested for respiratory-chain complex II activity, lipoperoxidation, and aconitase activity by spectrophotometric assays, in the presence of reduced iron (Fe2+), oxidised iron (Fe3+), desferrioxamine, ascorbic acid, and idebenone. The Friedreichʹs ataxia patients (aged 11 years, 19 years, and 21 years) underwent ultrasonographic heart measurements at baseline and after 4–9 months of idebenone (5 mg/kg daily). Findings Fe2+ (but not Fe3+) decreased complex II activity and increased lipoperoxidation in heart homogenate. Addition of ascorbate or desferrioxamine increased some of the ironinduced adverse effects. Idebenone protected against these effects. In the three patients, left-ventricular mass index decreased from baseline to 4–9 months of idebenone treatment (patient 1, 145 g to 114 g; patient 2, 215 g to 151 g; patient 3, 408 g to 279 g). Interpretation Our in-vitro data suggest that both iron chelators and antioxidant drugs that may reduce iron are potentially harmful in patients with Friedreichʹs ataxia. Conversely, our preliminary findings in patients suggest that idebenone protects heart muscle from iron-induced injury.
  • Journal title
    The Lancet
  • Serial Year
    1999
  • Journal title
    The Lancet
  • Record number

    549138